The question we are dancing around in episode 3 of NUKED is whether locking down isotopes supply chains are really the only way to play the radiopharmaceutical game.
We ask Clarity Pharmaceutical executive chair Alan Taylor and Radiopharm Theranostics executive chair Paul Hopper how their companies are instead owning the IP, or banking a portfolio of IP licences, to create the kind of economic moat that others are pursuing via isotope supply chains.
Podden och tillhörande omslagsbild på den här sidan tillhör
Soundcraft Media. Innehållet i podden är skapat av Soundcraft Media och inte av,
eller tillsammans med, Poddtoppen.
